P53 mutations in lymphomas: Position matters

Blood

Volumn 112, Issue 8, 2008, Pages 2997-2998

  Levine, Arnold J ^a   Vosburgh, Evan ^b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b Institute for Advanced Study

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CODON; DNA BINDING; DNA DAMAGE; ENVIRONMENTAL STRESS; FOLLICULAR LYMPHOMA; GENE MUTATION; HUMAN; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; MISSENSE MUTATION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

EID: 61849140041     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-167718     Document Type: Note

References (7)

1. Levine AJ, Hu W, Feng Z. The p53 pathway: what questions remain to be explored? Cell Death Differ. 2006; 13:1027-1036.
2. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49-53.
3. Borresen AL, Andersen TI, Eyfjord JE, et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer. 1995; 14:71-75.
4. Olivier M, Langerod A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006;12:1157-1167.
5. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999;18:477-485.
6. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol. 2007;9:573-580.
7. Lozano G, Zambetti GP. What have animal models taught us about the p53 pathway? J Pathol. 2005;205:206-220.